To coincide with World AIDS Day, the U.S. Department of Health and Human Services and World Health Organization both released revised guidelines calling for earlier initiation of antiretroviral therapy (ART) for HIV.
The updated DHHS "Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents," issued December 1, raise the CD4 T-cell threshold for starting treatment from 350 to 500 cells/mm3.
The revision also adds the first integrase inhibitor, raltegravir (Isentress), as a "preferred" drug for first-line therapy. Efavirenz (Sustiva), ritonavir-boosted atazanavir (Reyataz), and boosted darunavir (Prezista) are the other three preferred options – all used with tenofovir plus emtricitabine (the drugs in the Truvada combination pill) – while lopinavir/ritonavir (Kaletra) has been demoted to an "alternative."
Read the rest.
No comments:
Post a Comment